Article
Oncology
Miranda M. Tallman, Abigail A. Zalenski, Ian Stabl, Morgan S. Schrock, Luke Kollin, Eliane de Jong, Kuntal De, Treg M. Grubb, Matthew K. Summers, Monica Venere
Summary: The goal of this study was to validate the therapeutic efficacy of a small molecule inhibitor, KIF11, in increasing the sensitivity of glioblastoma (GBM) cells to radiotherapy and improving overall survival in patients. The results showed that KIF11 inhibition could radiosensitize GBM cells and improve overall survival in preclinical mouse models of GBM. These findings offer a new therapeutic modality that can increase the efficacy of radiotherapy for GBM with the ultimate goal of improving patient outcomes.
Editorial Material
Oncology
Gary J. Doherty, Bruno H. R. de Paula
Summary: This editorial discusses a recent Phase 1b trial of nabiximols oromucosal spray in combination with dose-intense temozolomide in patients with recurrent GBM, highlighting the lack of clinical and safety data despite promising preclinical results on the potential anti-cancer effects of cannabinoids in GBM.
BRITISH JOURNAL OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Weichen Duan, Miao Yu, Jiajia Chen
Summary: The BET family proteins, including BRD2, BRD3 and BRD4, are epigenetic readers that play multiple roles in the tumorigenesis and growth of various human malignancies. This review focuses on summarizing the roles and mechanisms of BRD4 in the initiation and development of glioblastoma, and evaluates the use of various BRD4 inhibitors and degraders as novel treatment strategies against glioblastoma.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Oncology
Ketao Jin, Chunsen Mao, Lin Chen, Lude Wang, Yuyao Liu, Jianlie Yuan
Summary: Glioblastoma multiforme (GBM) is an aggressive type of brain tumor with poor response to traditional therapies. The immunosuppressive microenvironment in GBM poses a challenge for immunotherapy, with the adenosinergic pathway playing a key role in suppressing antitumor immune responses. Targeting this pathway in combination therapies shows promise in reinvigorating antitumor responses and overcoming chemoresistance.
Article
Biology
Francesca Santicchia, Lucas Armand Wauters, Ben Dantzer, Rupert Palme, Claudia Tranquillo, Damiano Preatoni, Adriano Martinoli
Summary: Animals use the stress response to cope with environmental perturbations. In response to stress, vertebrate animals may release glucocorticoids (GCs) which can have both beneficial and detrimental effects. The study shows that native red squirrels can habituate to prolonged contact with invasive grey squirrels, reducing the potential harmful effects of chronic elevation in GCs.
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Jeannette Hofmeijer, Florien Ham, Gert Kwakkel
Summary: Repetitive transcranial magnetic stimulation has the potential to improve motor and cognitive outcomes after stroke, but the evidence of efficacy is challenged by unexplained variability in small sampled trials. Future large trials should collect individual patient data and conduct sufficiently powered subgroup analyses, as well as protocolized time-locked training of target behavior.
Review
Immunology
Angeliki Datsi, Ruediger V. Sorg
Summary: Dendritic cell vaccination (DCV) is a promising immunotherapy for treating glioblastomas, with numerous trials showing potential but some controlled studies failing to detect a survival benefit. Further exploration is needed to fully understand the potential of this therapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Joao Victor Roza Cruz, Carolina Batista, Bernardo de Holanda Afonso, Magna Suzana Alexandre-Moreira, Luiz Gustavo Dubois, Bruno Pontes, Vivaldo Moura Neto, Fabio de Almeida Mendes
Summary: Glioblastomas are the most common and aggressive primary brain tumors in adults, and their treatment is challenging. Current research focuses on understanding chemoresistance mechanisms, improving drug delivery, and utilizing viruses to specifically target tumor cells.
Review
Biochemistry & Molecular Biology
Karolina Pellot I. Ortiz, Julian S. Rechberger, Leo F. Nonnenbroich, David J. Daniels, Jann N. Sarkaria
Summary: Inhibition of MDM2 and p53 interaction is a promising strategy for treating cancer, particularly glioblastoma. Multiple MDM2 inhibitors are being tested for their potential in glioblastoma therapy, with encouraging results seen in cell culture and animal models. Combination therapy with established treatments like radiation and chemotherapy, as well as other molecularly targeted therapies, could enhance therapeutic response. However, the efficacy of MDM2 inhibitors, both alone and in combination, is still being evaluated in ongoing clinical trials for glioblastoma patients.
Review
Health Care Sciences & Services
Diogo Roque, Nuno Cruz, Hugo Alexandre Ferreira, Catarina Pinto Reis, Nuno Matela, Manuel Herculano-Carvalho, Rita Cascao, Claudia C. Faria
Summary: Glioblastoma is a malignant brain tumor with limited treatment options. Nanoparticles provide a promising approach for the treatment of glioblastoma by overcoming the blood-brain barrier and reducing systemic side effects.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Cell Biology
Alessandro Tancredi, Olga Gusyatiner, Pierre Bady, Michelle C. Buri, Remy Lomazzi, Davide Chiesi, Mahmoud Messerer, Monika E. Hegi
Summary: Bromodomain and extra-terminal tail (BET) proteins are potential epigenetic targets in cancer, including glioblastoma. BET inhibitors disrupt the histone code-gene transcription link. BET-induced differential gene expression in glioblastoma derived-spheres revealed 6 distinct response patterns. The O-6-methylguanine-DNA methyltransferase (MGMT) gene, a known resistance factor for glioblastoma treatment, showed consistent downregulation in response to BET inhibitors.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Muhammad AbdEl-haq, Awanish Kumar, Fatima-ezzahra Ait Mohand, Nataly Kravchenko-Balasha, Yakir Rottenberg, Abraham J. Domb
Summary: The study investigated the development of paclitaxel-loaded polymeric nanoparticles for brain tumor treatment. Poly(lactide-glycolide) (PLGA) nanoparticles with a size of 216 nm and containing 10% w/w paclitaxel were administered through intranasal and intravenous routes to rats. Both routes of administration resulted in significant accumulation of paclitaxel in brain tissue, liver, and kidney, with no observed toxicity. The anti-proliferative effect of the nanoparticles on glioblastoma tumor cells was similar to that of free paclitaxel.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Maria Peleli, Ivi Antoniadou, Dorival Mendes Rodrigues-Junior, Odysseia Savvoulidou, Laia Caja, Antonia Katsouda, Daniel F. J. Ketelhuth, Jane Stubbe, Kirsten Madsen, Aristidis Moustakas, Andreas Papapetropoulos
Summary: This study reveals that CTH expression contributes to tumorigenesis and angiogenesis in glioblastoma. Inhibition of CTH can attenuate GBM cell proliferation, migration, and stem cell formation. Higher CTH expression is associated with worse overall survival and resistance to temozolomide in human gliomas.
Review
Pharmacology & Pharmacy
Nikhil Pandey, Pavlos Anastasiadis, Christine P. Carney, Pranjali P. Kanvinde, Graeme F. Woodworth, Jeffrey A. Winkles, Anthony J. Kim
Summary: This review focuses on drug delivery strategies and nanotherapeutic technologies targeting brain-invading cancer cells and highlights the importance of treatments for invasive cells.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Review
Immunology
Stephen C. C. Frederico, Corbin Darling, John P. P. Bielanin, Alexandra C. C. Dubinsky, Xiaoran Zhang, Constantinos G. G. Hadjipanayis, Gary Kohanbash
Summary: Brain tumors, particularly glioblastomas, are highly aggressive and often recur despite current treatment options. Immune checkpoint inhibitors have shown success in treating non-central nervous system cancers, but have been largely disappointing for GBM patients. This review explores the potential benefits of neoadjuvant immune checkpoint inhibition, which reduces tumor burden and enhances anti-tumor immune response, and suggests that this approach may provide a survival benefit for GBM patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Mindell Seidlin, Robert Holzman, Pamela Knight, Bruce Korf, Vanessa Rangel Miller, David Viskochil, Annette Bakker
Review
Neurosciences
Annette C. Bakker, Salvatore La Rosa, Larry S. Sherman, Pamela Knight, Hyerim Lee, Patrice Pancza, Marco Nievo
PROGRESS IN NEUROBIOLOGY
(2017)
Article
Genetics & Heredity
Renske Oegema, David Baillat, Rachel Schot, Leontine M. van Unen, Alice Brooks, Sima Kheradmand Kia, A. Jeannette M. Hoogeboom, Zheng Xia, Wei Li, Matteo Cesaroni, Maarten H. Lequin, Marjon van Slegtenhorst, William B. Dobyns, Irenaeus F. M. de Coo, Frans W. Verheijen, Andreas Kremer, Peter J. van der Spek, Daphne Heijsman, Eric J. Wagner, Maarten Fornerod, Grazia M. S. Mancini
Article
Genetics & Heredity
Michael J. Fisher, Allan J. Belzberg, Peter de Blank, Thomas De Raedt, Florent Elefteriou, Rosalie E. Ferner, Marco Giovannini, Gordon J. Harris, Michel Kalamarides, Matthias A. Karajannis, AeRang Kim, Conxi Lazaro, Lu Q. Le, Wei Li, Robert Listernick, Staci Martin, Helen Morrison, Eric Pasmant, Nancy Ratner, Elisabeth Schorry, Nicole J. Ullrich, David Viskochil, Brian Weiss, Brigitte C. Widemann, Yuan Zhu, Annette Bakker, Eduard Serra
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2018)
Review
Oncology
Robert J. Allaway, Sara J. C. Gosline, Salvatore La Rosa, Pamela Knight, Annette Bakker, Justin Guinney, Lu Q. Le
BRITISH JOURNAL OF CANCER
(2018)
Article
Anatomy & Morphology
Amira A. H. Ali, Beryl Schwarz-Herzke, Shakila Mir, Benita Sahlender, Marion Victor, Boris Goerg, Martin Schmuck, Katharina Dach, Ellen Fritsche, Andreas Kremer, Charlotte von Gall
BRAIN STRUCTURE & FUNCTION
(2019)
Article
Genetics & Heredity
Rosalie E. Ferner, Annette Bakker, Ype Elgersma, D. Gareth R. Evans, Marco Giovannini, Eric Legius, Alison Lloyd, Ludwine M. Messiaen, Scott Plotkin, Karlyne M. Reilly, Aaron Schindeler, Miriam J. Smith, Nicole J. Ullrich, Brigitte Widemann, Larry S. Sherman
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2019)
Editorial Material
Medicine, Research & Experimental
Salvatore La Rosa, Vidya Browder, Annette C. Bakker, Jaishri O. Blakeley, Sharad K. Verma, Ling M. Wong, Jill Morris, Naba Bora
EMBO MOLECULAR MEDICINE
(2020)
Editorial Material
Biochemical Research Methods
Susanne Hollmann, Marcus Frohme, Christoph Endrullat, Andreas Kremer, Domenica D'Elia, Babette Regierer, Alina Nechyporenko
PLOS COMPUTATIONAL BIOLOGY
(2020)
Article
Multidisciplinary Sciences
Antonio Federico, Veera Hautanen, Nils Christian, Andreas Kremer, Angela Serra, Dario Greco
Article
Medicine, Research & Experimental
Mika M. Tabata, Shufeng Li, Pamela Knight, Annette Bakker, Kavita Y. Sarin
Article
Dermatology
Steven D. Rhodes, Frank McCormick, Ross L. Cagan, Annette Bakker, Verena Staedtke, Ina Ly, Matthew R. Steensma, Sang Y. Lee, Carlos G. Romo, Jaishri O. Blakeley, Kavita Y. Sarin
Summary: Cutaneous neurofibromas (cNFs) are the most common tumors in neurofibromatosis type 1 patients, and there is a lack of effective interventions for their treatment. To develop new therapies, it is essential to understand the biology of cNFs, including the role of RAS signaling and downstream pathways. This review provides an overview of the current knowledge on RAS signaling in cNF pathogenesis and therapeutic development.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Federica Fabro, Trisha V. Kers, Kate J. Feller, Cecile Beerens, Ioannis Ntafoulis, Ahmed Idbaih, Maite Verreault, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Annette T. Byrne, Alice C. O'Farrell, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Andreas Kremer, Romain Tching Chi Yen, Miao-Ping Chien, Martine L. M. Lamfers, Sieger Leenstra
Summary: Chemotherapy using temozolomide is the standard treatment for glioblastoma, but temozolomide resistance remains a challenge. This study reveals the association between resistance and heterogeneity in glioblastoma, and identifies distinct phenotypic behaviors and gene expressions in response to temozolomide. The adaptability and heterogeneity of glioblastoma cells contribute to their ability to survive and develop resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Respiratory System
Johannes A. Kroes, Aruna T. Bansal, Emmanuelle Berret, Nils Christian, Andreas Kremer, Anna Alloni, Matteo Gabetta, Chris Marshall, Scott Wagers, Ratko Djukanovic, Celeste Porsbjerg, Dominique Hamerlijnck, Olivia Fulton, Anneke Ten Brinke, Elisabeth H. Bel, Jacob K. Sont
Summary: Real-world evidence from multinational disease registries plays a crucial role in validating randomized controlled trials, identifying phenotypes, monitoring disease progression, predicting drug response, and detecting rare side-effects. The use of open-access technologies allows for the harmonization and analysis of patient data without violating privacy regulations.